Chemomab Ltd. is a clinical-stage biopharmaceutical company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need.
Chemomab is making great strides with its novel CM-101 proprietary platform, which hinders the fundamental function of the soluble chemokine CCL24 as a regulator of major inflammatory and fibrotic pathways in multiple fibrosis-related disorders.
CM-101, the company’s lead clinical candidate, is a first-in-class monoclonal antibody that targets CCL24. Chemomab has shown that CM-101 interferes with the underlying biology of fibrosis using a novel and differentiated mechanism of action.
Chemomab is actively advancing CM-101 into phase 2 studies to treat patients with liver fibrosis (Primary Sclerosing Cholangitis and Non-alcoholic Steatohepatitis) and patients suffering from skin and lung fibrosis (Systemic Sclerosis).
Chemomab is making great strides with its novel CM-101 proprietary platform, which hinders the fundamental function of the soluble chemokine CCL24 as a regulator of major inflammatory and fibrotic pathways in multiple fibrosis-related disorders.
CM-101, the company’s lead clinical candidate, is a first-in-class monoclonal antibody that targets CCL24. Chemomab has shown that CM-101 interferes with the underlying biology of fibrosis using a novel and differentiated mechanism of action.
Chemomab is actively advancing CM-101 into phase 2 studies to treat patients with liver fibrosis (Primary Sclerosing Cholangitis and Non-alcoholic Steatohepatitis) and patients suffering from skin and lung fibrosis (Systemic Sclerosis).
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Israel
Year Founded:
2011
Main Therapeutic Focus:
Orphan/Rare Diseases
Lead Product in Development:
CM-101, Anti-CCL24 neutralizing mAb
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
